Press releases
- Cybin to Participate at the 27th Annual Milken Institute Global Conference
- Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
- Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
- Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
- Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
- Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
- Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
- Announces Oversubscribed Private Placement of U.S. $150 Million
- Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
More ▼
Key statistics
On Friday, Cybin Inc (R7E1:FRA) closed at 0.32, 50.94% above the 52 week low of 0.212 set on Jun 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.32 |
---|---|
High | 0.32 |
Low | 0.32 |
Bid | 0.32 |
Offer | 0.3417 |
Previous close | 0.3218 |
Average volume | 1.81k |
---|---|
Shares outstanding | 759.69m |
Free float | 709.08m |
P/E (TTM) | -- |
Market cap | 349.46m CAD |
EPS (TTM) | -0.282 CAD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:13 BST.
More ▼